Skip to main content
. 2020 Feb;9(1):43–50. doi: 10.21037/tp.2019.12.03

Figure 2.

Figure 2

Frequency of RAS and Ras-pathway mutations in pediatric hematologic malignancies. (A) RAS and Ras-pathway mutations in all patients; (B) RAS and Ras-pathway mutations in ALL; (C) percentage of RAS and Ras pathway aberrations in AML; (D) frequency of genetic mutations identified to predict hyperactive Ras signaling in sequenced patients. ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia.